
浏览全部资源
扫码关注微信
215006 江苏 苏州,苏州大学附属第一医院呼吸与危重症医学科,苏州大学呼吸疾病研究所
[黄建安,E-mail:huang_jian_an@163.com HUANG Jian'an, E-mail: huang_jian_an@163.com
收稿:2022-08-31,
修回:2022-10-07,
纸质出版:2022-12-30
移动端阅览
蔡馨, 刘泽毅, 黄建安. CPNE3调控非小细胞肺癌细胞增殖、迁移、侵袭及其相关机制研究[J]. 陆军军医大学学报, 2022,44(24):2507-2513.
Xin CAI, Zeyi LIU, Jian'an HUANG. Mechanism of CPNE3 regulating proliferation, migration and invasion of non-small cell lung cancer cells[J]. Journal of Army Medical University, 2022, 44(24): 2507-2513.
蔡馨, 刘泽毅, 黄建安. CPNE3调控非小细胞肺癌细胞增殖、迁移、侵袭及其相关机制研究[J]. 陆军军医大学学报, 2022,44(24):2507-2513. DOI: 10.16016/j.2097-0927.202208227.
Xin CAI, Zeyi LIU, Jian'an HUANG. Mechanism of CPNE3 regulating proliferation, migration and invasion of non-small cell lung cancer cells[J]. Journal of Army Medical University, 2022, 44(24): 2507-2513. DOI: 10.16016/j.2097-0927.202208227.
目的
2
探讨CPNE3对非小细胞肺癌(non-small cell lung cancer,NSCLC)细胞株A549增殖、迁移和侵袭能力的影响及其作用机制。
方法
2
通过癌症和肿瘤基因图谱(the cancer genome atlas,TCGA)的公共数据分析CPNE3在NSCLC中的表达及其与患者预后的关系。利用Western blot方法检测CPNE3在正常支气管上皮细胞株BEAS-2B和肺癌细胞株中的表达。在A549细胞中转染CPNE3的干扰序列,利用CCK-8、克隆形成、Transwell实验检测细胞增殖、迁移和侵袭能力,Western blot法检测下游增殖、转移相关蛋白水平的变化。构建CPNE3过表达稳转细胞株,取10只雌性BALB/c nude小鼠分为对照组和过表达CPNE3组(
n
=5),构建裸鼠皮下移植瘤模型,观察过表达CPNE3对A549细胞成瘤能力的影响。
结果
2
NSCLC组织中CPNE3表达升高(
P
<
0.05),其高表达与患者的不良预后相关(
P
<
0.01),CPNE3在肺癌细胞株中表达升高(
P
<
0.01),干扰CPNE3后细胞的增殖能力、克隆形成能力下降(
P
<
0.001,
P
<
0.01),迁移和侵袭能力下降(
P
<
0.01,
P
<
0.01),并伴随着p-AKT、p-ERK和p-EGFR蛋白的下调(
P
<
0.001,
P
<
0.001,
P
<
0.01)。过表达CPNE3在体内促进移植瘤的生长(
P
<
0.001),并伴随着p-AKT、p-ERK和p-EGFR蛋白的上调(
P
<
0.05,
P
<
0.05,
P
<
0.01)。
结论
2
干扰CPNE3可以抑制A549细胞的增殖、迁移和侵袭能力,过表达CPNE3可以增强A549细胞在体内的增殖能力,其作用机制与EGFR信号通路及其下游的AKT/ERK信号通路相关。
Objective
2
To investigate the effect of CPNE3 on the proliferation
migration and invasion of non-small cell lung cancer (NSCLC) cell line A549 and its underlying mechanism.
Methods
2
The expression of CPNE3 in NSCLC and its relationship with prognosis were analyzed based on the data from the cancer genome atlas (TCGA) database. Western blotting was used to detect the expression of CPNE3 in normal bronchi
al epithelial cell line BEAS-2B and lung cancer cell lines. The si-RNAs of CPNE3 were transfected into A549 cells. The abilities of cell proliferation
migration and invasion were detected by CCK-8 assay
colony formation assay
and Transwell assay
respectively
and the expression levels of downstream proteins related to proliferation and metastasis were detected by Western blotting. After the A549 cells with stable overexpression of CPNE3 were established
the cells with overexpression or not were respectively employed to construct lung carcinoma xenograft model in female BALB/c nude mice (
n
=5 for control and overexpression mice
respectively). Then the tumor growth was observed to determine the effect of CPNE3 overexpression on the tumorigenicity of A549 cells.
Results
2
The expression of CPNE3 was increased in NSCLC tissues (
P
<
0.05)
and its high expression was correlated with poor prognosis (
P
<
0.01). Consistently
the expression of CPNE3 was increased in lung cancer cell lines (
P
<
0.01). After the knockdown of CPNE3
the proliferation and colony formation (
P
<
0.001
P
<
0.01)
and migration and invasion abilities (
P
<
0.01
P
<
0.01) were significantly inhibited in A549 cells
accompanied with decreased phosphorylation levels of AKT
ERK
and EGFR (
P
<
0.001
P
<
0.001
P
<
0.01). Overexpression of CPNE3 promoted cell proliferation
in vivo
(
P
<
0.001)
and upregulated phosphorylation of AKT
ERK
and EGFR (
P
<
0.05
P
<
0.05
P
<
0.01).
Conclusion
2
Knocking CPNE3 down can inhibit the proliferation
migration and invasion of A549 cells
while its overexpression can promote the proliferation ability of A549 cells
in vivo
which may be related to EGFR signaling pathway and downstream AKT/ERK signaling pathway.
SUNG H, FERLAY J, SIEGEL R L, et al . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J ] . CA Cancer J Clin. 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[erratum: Global cancer statistics 2018: GLOBOCAN estimates ofincidence and mortality worldwide for 36 cancers in 185 countries[J ] . CA Cancer J Clin, 2020, 70(4): 313. DOI: 10.3322/caac.21609 http://dx.doi.org/10.3322/caac.21609 .
HERBST R S, MORGENSZTERN D, BOSHOFF C. The biology and management of non-small cell lung cancer[J]. Nature, 2018, 553(7689): 446-454. DOI: 10.1038/nature25183.
SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer Statistic[J ] . CA Cancer J Clin, 2021, 71(1): 7-33. DOI: 10.3322/caac.21654.
TOMSIG J L, SNYDER S L, CREUTZ C E. Identification of targets for calcium signaling through the copine family of proteins: characterization of a coiled-coil copine-binding motif[J]. J Biol Chem, 2003, 278(12): 10048-10054. DOI: 10.1074/jbc.M212632200.
CAUDELL E G, CAUDELL J J, TANG C H, et al . Characterization of human copine Ⅲ as a phosphoprotein with associated kinase activity[J ] . Biochemistry, 2000, 39(42): 13034-13043. DOI: 10.1021/bi001250v.
TANG H C, PANG P, QIN Z, et al . The CPNE family and their role in cancers[J ] . Front Genet, 2021, 12: 689097. DOI: 10.3389/fgene.2021.689097.
HEINRICH C, KELLER C, BOULAY A, et al . Copine-Ⅲ interacts with ErbB2 and promotes tumor cell migration[J ] . Oncogene, 2010, 29(11): 1598-1610. DOI: 10.1038/on c.2009.456.
SUN B, LI Y M, ZHOU Y M, et al . Circulating exosomal CPNE3 as a diagnostic and prognostic biomarker for colorectal cancer[J ] . J Cell Physiol, 2019, 234(2): 1416-1425. DOI: 10.1002/jcp.26936.
CHEN Z, JIANG Z K, ZHANG W Z, et al . Silencing the expression of copine-Ⅲ enhances the sensitivity of hepatocellular carcinoma cells to the molecular targeted agent sorafenib[J ] . Cancer Manag Res, 2018, 10: 3057-3067. DOI: 10.2147/CMAR.S167781.
ZHANG D N, WANG X Y, WANG X, et al . CPNE3 regulates the cell proliferation and apoptosis in human Glioblastoma via the activation of PI3K/AKT signaling pathway[J ] . J Cancer, 2021, 12(24): 7277-7286. DOI: 10.7150/jca.60049.
LIN H C, ZHANG X, LIAO L, et al . CPNE3 promotes migration and invasion in non-small cell lung cancer by interacting with RACK1 via FAK signaling activation[J ] . J Cancer, 2018, 9(22): 4215-4222. DOI: 10.7150/jca.25872.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621